307 results on '"Haupt, Axel"'
Search Results
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
3. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
5. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
6. LBO-001 Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial
7. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
8. Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial
9. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
10. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
11. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
12. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
13. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
14. New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state.
15. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes
16. Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
17. Preface
18. Organic and Inorganic Fluorine Chemistry
19. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
20. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
21. 52-OR: Effect of Oral Nonpeptide GLP-1 Receptor Agonist Orforglipron (LY3502970) in Participants with Obesity or Overweight—A Phase 2 Study
22. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post-Hoc Analysis
23. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
24. Abstract 13426: The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
25. A novel once-weekly Basal Insulin Fc achieved similar glycaemic control with a comparable safety profile versus insulin degludec in patients with type 1 diabetes
26. Tirzepatide Reduces Appetite, Energy Intake and Fat Mass in People with T2D
27. LY3437943 (LY), A Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2D after 12 Weeks of Treatment
28. Effects of tirzepatide versus insulin glargine 100U/ml on kidney outcomes in people with type 2 diabetes in SURPASS-4
29. Once-weekly Basal Insulin Fc (BIF) demonstrated similar glycaemic control to once-daily Insulin Degludec (IDeg) in insulin-naïve patients with Type 2 Diabetes (T2D)
30. Once Weekly Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily Insulin Degludec in Insulin-naïve Patients with Type 2 Diabetes, A Phase 2 Randomized Control Trial
31. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
32. Novel Once Weekly Basal Insulin Fc (BIF) Achieved Similar Glycemic Control with A Comparable Safety Profile Versus Insulin Degludec in Patients with Type 1 Diabetes (T1D)
33. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
34. Tirzepatide reduces appetite, energy intake and fat mass in people with T2D
35. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
36. Integration of a LOHC storage into a heat-controlled CHP system
37. Synthesis of fluorine-containing 1,10-phenanthrolines using mild versions of Skraup and Doebner-von Miller reactions
38. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
39. The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying.
40. Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
41. Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
42. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes
43. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
44. A Versatile Silver(I) Pentafluorooxosulfate Reagent for the Synthesis of OSF 5 Compounds
45. 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D
46. 714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
47. 340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment
48. 17-OR: ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4
49. 215-OR: Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily (QD) Insulin Degludec (DEG) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)
50. Glycemic Control with Once Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.